Respiratory Syncytial Virus(RSV)

Our team at IBT Bioservices has extensive experience in preclinical testing services to assess the viability and effectiveness of novel therapies against respiratory illnesses such as RSV, influenza, SARS-CoV-2.


RSV is highly contagious and spreads through respiratory droplets when an infected person coughs or sneezes.

Age Groups Affected

RSV can infect individuals of all ages, it is most severe in infants and young children. Older adults and individuals with weakened immune systems are also at risk of severe complications.


Common symptoms include cough, runny nose, sneezing, fever, and wheezing. In infants and young children, more severe symptoms such as difficulty breathing, rapid breathing, and cyanosis may occur.


Member of the Paramyxoviridae family and the Pneumovirus genus

IBT Bioservices has developed an extensive assortment of reagents to facilitate the advancement of therapeutics and assay development, thus supporting the progress of research on respiratory viruses. We offers a diverse array of products and services designed to facilitate respiratory virus research, ranging from viral proteins to antiserum and antibodies.



Purified monoclonal and polyclonal antibodies

Recombinant proteins

Rest assured, our reagents are of exceptional quality, and they are available for purchase to support your research endeavors.

Our Preclinical Testing Services For Filoviruses Encompass A Wide Range Of Assessments, Including:


Our in vitro RSV services include antiviral screening assays to identify potential candidates with antiviral activity against RSV. We utilize high-throughput screening techniques to evaluate large compound libraries, natural products, or novel drug candidates for their ability to inhibit viral replication. Our screening assays enable the identification of lead compounds with promising antiviral properties for further development.

Vaccine Evaluation

Our in vivo RSV services include vaccine evaluation studies using animal models. We assess the immunogenicity and protective efficacy of RSV vaccine candidates, helping you determine their ability to induce robust immune responses and provide protection against RSV infection. We closely monitor key parameters, including viral load, immune response, and behavioral changes, to evaluate the effectiveness of the tested therapies


We provide animal models, such as cotton rats, for studying RSV infection, pathogenesis, and evaluating the efficacy of potential interventions. Our animal models closely mimic the clinical and immunological aspects of RSV infection in humans, providing valuable insights into viral replication in the lungs, host immune responses, disease progression, pathology, and treatment outcomes. Our in vivo models help assess vaccine candidates, antiviral therapies, and evaluate their safety and efficacy.

When conducting in-life efficacy studies for RSV, it is essential to consider certain factors:

Animal Strain Selection

The cotton rat (Sigmodon hispidus) is a widely used animal model for evaluating therapeutics against non- adapted RSV infection.

Formulation and Treatment Route

Cotton rats are sensitive to handling and isoflurane inhalation, which creates challenges when determining the optimal treatment route and regimen. IBT’s experienced handlers can help limit stress and assist investigators in identifying an ideal therapeutic regimen.


Determining the ideal treatment route and regimen for your therapeutic route is vital to determine the potency of your therapeutic and its ability to inhibit viral replication.


Proper formulation of drug candidates and vaccines are crucial to determine their effectiveness. Including appropriate controls can help identify the enhancing effects of the drug or additives or if they provide protection.

Therapeutic Target and Virus Strain

Selection of virus strain based on the therapeutics method of action and target

Endpoint Assays and Readouts

Collection of affected organs, such as lungs, BAL, and nasal washes, allows for further evaluation of viral load, cellular immune response, and histopathology.

We work with investigators to determine the best virus model for their therapeutic or vaccine.

At IBT, we offer a wide range of specialized services and expertise in RSV research. Our experienced team of scientists and researchers provide high-quality data, reliable results, and customized solutions to meet your specific research needs. Whether you require in vitro assays to study RSV biology or in vivo studies to evaluate interventions, we are here to support your RSV research and development efforts.Contact us today to discuss your specific RSV service requirements and discover how our expertise can accelerate your research, advance RSV interventions, and contribute to global efforts in combating RSV infections. Together, let’s make strides in RSV research and improve public health outcomes.